Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Raw Materials (2019 - 2025)

CorMedix has reported Raw Materials over the past 5 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Raw Materials at $3.6 million for Q4 2025, up 227.18% from a year ago — trailing twelve months through Dec 2025 was $3.6 million (up 227.18% YoY), and the annual figure for FY2025 was $3.6 million, up 227.18%.
  • Raw Materials reached $3.6 million in Q4 2025 per CRMD's latest filing, down from $7.0 million in the prior quarter.
  • Across five years, Raw Materials topped out at $7.0 million in Q3 2025 and bottomed at $603545.0 in Q3 2024.
  • Median Raw Materials over the past 3 years was $1.1 million (2025), compared with a mean of $2.1 million.
  • The largest annual shift saw Raw Materials fell 27.17% in 2024 before it skyrocketed 1062.75% in 2025.
  • Over 3 years, Raw Materials stood at $1.5 million in 2023, then decreased by 27.17% to $1.1 million in 2024, then soared by 227.18% to $3.6 million in 2025.
  • Business Quant data shows Raw Materials for CRMD at $3.6 million in Q4 2025, $7.0 million in Q3 2025, and $1.1 million in Q2 2025.